Shares of HNI (HNI) have gained 8.8% over the past four weeks to close the last trading session at $47.26, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $69.50 indicates a potential upside of 47.1%.The average comprises four short-term price targets ranging from a low of $63 to a high of $80, with a standard deviation of $7.59. While the lowest estimate indicates an increase o ...

Core Viewpoint - Arcturus Therapeutics (ARCT) has seen a 7.5% increase in share price over the past four weeks, closing at $12.81, with analysts suggesting a potential upside of 371.4% based on a mean price target of $60.38 [1][12]. Price Targets and Analyst Estimates - The mean price target is derived from eight short-term estimates, with a standard deviation of $33.97, indicating variability among analysts [2]. - The lowest price target of $32 suggests a 149.8% increase, while the highest target of $140 indicates a potential surge of 992.9% [2]. - A low standard deviation among price targets suggests a strong consensus among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates upward, which is a positive indicator for potential stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 42.1% over the past month, with four estimates rising and no negative revisions [12]. - ARCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them can be misleading, as they often do not accurately predict stock price movements [3][7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Shares of Semtech (SMTC) have gained 9.4% over the past four weeks to close the last trading session at $37.33, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $56.33 indicates a potential upside of 50.9%.The average comprises 12 short-term price targets ranging from a low of $43 to a high of $68, with a standard deviation of $8.32. While the lowest estimate indicates an increas ...

Catalyst Pharmaceutical (CPRX) closed the last trading session at $24.96, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34 indicates a 36.2% upside potential.The average comprises eight short-term price targets ranging from a low of $31 to a high of $40, with a standard deviation of $2.98. While the lowest estimate indicates an increase of 24.2% from the current pri ...

Backblaze, Inc. (BLZE) closed the last trading session at $5.70, gaining 25.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.83 indicates a 90% upside potential.The average comprises six short-term price targets ranging from a low of $8 to a high of $14, with a standard deviation of $1.94. While the lowest estimate indicates an increase of 40.4% from the current price level, ...

Shares of Oric Pharmaceuticals, Inc. (ORIC) have gained 44.1% over the past four weeks to close the last trading session at $8.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.90 indicates a potential upside of 131.3%.The average comprises 10 short-term price targets ranging from a low of $12 to a high of $25, with a standard deviation of $4.04. While the lowest estimate ...

Pan American Silver (PAAS) closed the last trading session at $24.20, gaining 0.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.23 indicates a 29.1% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $4.44. While the lowest estimate of $26 indicates a 7.4% increase from the current price level, the most optimistic analyst ...

Eastern Bankshares, Inc. (EBC) closed the last trading session at $14.78, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.25 indicates a 30.2% upside potential.The average comprises four short-term price targets ranging from a low of $16 to a high of $23, with a standard deviation of $2.99. While the lowest estimate indicates an increase of 8.3% from the current pr ...

Core Viewpoint - Provident Financial (PFS) shows potential for significant upside, with a mean price target of $21.50 indicating a 28.1% increase from the current price of $16.78 [1] Price Targets and Analyst Consensus - The average price targets from analysts range from a low of $18 to a high of $24, with a standard deviation of $2.17, suggesting a moderate agreement among analysts [2] - The lowest estimate indicates a 7.3% increase, while the highest suggests a 43% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about PFS's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with two estimates moving higher and no negative revisions [12] - PFS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $10.65, gaining 35.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.05 indicates a 41.3% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $0.74. While the lowest estimate of $14.20 indicates a 33.3% increase from the current price level, the most optim ...